Estrella Immunopharma, Inc. (ESLA) · Oct 29, 2026 · Exec change
CEO change — Pussinen replaces Liu as CEO; Liu becomes President and CSO
Estrella’s CEO change formalizes a biotech leadership upgrade, while employment amendments reveal deferred salaries and urgent financing dependence.
Estrella is a cash-constrained clinical-stage biotech trying to move EB103 through the STARLIGHT-1 Phase I/II trial while developing the related EB104 program; its latest quarterly filing showed roughly $0.1 million of cash, an $8.3 million accrued liability to Eureka, and substantial doubt about continuing as a going concern. The leadership shift is now contractually locked in, but it was not new by the filing date. Cynthia Pussinen became CEO and board chair effective October 25, while Cheng Liu moved to President and Chief Scientific Officer and remained a director; that preserves scientific continuity but puts a more commercially and financing-oriented executive in charge as the company enters dose expansion. The appointment had already been publicly announced on October 26. The agreement states that Pussinen will serve as CEO and that the company will take steps to appoint her board chair. 〔0〕 The contract makes financing the trigger for higher executive pay, which is strategically revealing. Pussinen starts at $250,000, with automatic increases to $400,000, $450,000 and $525,000 as cumulative qualifying funding exceeds $35 million, $55 million and $75 million. That structure aligns compensation with capital raised, partnerships and milestone receipts—but also underscores that funding, not operating revenue, is the immediate business bottleneck. She also receives a 60% target cash bonus and a proposed 1 million-share option, subject to committee approval. The buried negative is that Estrella is still struggling to pay its existing executives. Amendments for Liu and CFO Jiandong Xu say the company has deferred their base salaries beginning with the May 22, 2026 pay date to preserve cash, and the amendment does not accelerate those unpaid amounts. 〔1〕 That makes the new CEO appointment more than a routine succession: it adds leadership capacity, but under terms that increase fixed compensation and severance obligations while liquidity remains unresolved. | Metric (Employment agreement) | Current / term | Trigger or comparison |
| Pussinen base salary (Section 3(a)) | $250,000 | $400,000 above $35M funding |
|---|---|---|
| Next salary step (Section 3(a)) | $450,000 | Above $55M funding |
| Maximum stated salary step (Section 3(a)) | $525,000 | Above $75M funding |
| Target annual bonus (Section 3(b)) | 60% of base salary | 55%-70% thereafter |
| Initial option (Section 3(f)(i)) | 1,000,000 shares | Committee approval required |
| Standard severance (Section 5(c)(ii)) | 12 months’ base salary | Without Cause / Good Reason |
| Change-in-control severance (Section 5(c)(iii)) | 12 months’ salary + 100% target bonus | Includes full equity acceleration |
Bottom line: The filing formalizes a potentially useful leadership upgrade, but the more important signal is financial: Estrella is adding executive obligations while existing salaries remain deferred and the clinical program still depends on new funding. 〔2〕
STARLIGHT-1 dose-expansion data and financing update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!